- Excellent sales momentum in 2017 with 10.2% growth in sales, at constant exchange rates and scope of consolidation:
- €2,288 million in sales
- Up 8.8% as reported
- Growth underpinned by all strategic product lines, particularly BIOFIRE FILMARRAY® which accounted for more than half of growth Group-wide
- Acceleration in growth in the EMEA and Asia-Pacific regions and steady double-digit increase for the Americas
- bioMérieux expects contributive operating income before non-recurring items to be in line with its previous target of between €330 million and €345 million
Alexandre Mérieux, Chairman and Chief Executive Officer, said: "All told, 2017 was a year of remarkable growth for bioMérieux, driven by a portfolio of complementary technological solutions and a broad geographic footprint. We are particularly pleased with the performance of BIOFIRE, which confirms the success of syndromic diagnosis for infectious diseases, and with the faster-paced growth in industrial applications. These results reflect a valid business strategy that meets the needs of healthcare professionals through high medical value diagnostic solutions, and of the industry sector in order to protect consumer’s health."